Mielóma multiplex: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• BCMA 134
• CD38 22
• GPRC5D 36
• CD19 31
• TP53 0
• STAT3 0
• CXCR4 3
• MYC 0
• BCL-2 2
• PI3K 1
• mTOR 0
• IL-6 0
• STING 0
• BRAF 2
• CD47 1
• HDAC 0
• AKT 0
• PD-1 1
• PD-L1 1
• CD20 3
• GLP-1 0
• JAK 0
• PTEN 0
• SGLT2 0
• TIGIT 0
• AMPK 0
• B7-H3 0
• NRAS 1
• CTLA-4 1
• ERK 0
• EZH2 0
• FTO 0
• IL-15 3
• JNK 0
• KRAS 1
• MAPK 0
• RAS 0
• CD22 2
• CD33 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• LAG-3 0
• MDM2 0
• METTL3 0
• NRF2 0
• BRCA1 0
• BRD4 0
• BTK 1
• CD123 1
• CD30 0
• CDK4/6 0
• GPX4 0
• HER2 0
• HIF-1 0
• HSP90 0
• MEK 0
• MET 0
• MUC1 0
• NTRK 0

4+ intézményből 4, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAMS · R01

  Modulation of Bone Formation and Fracture Repair During Cancer Development

  Washington University· Saint Louis, Egyesült Államok· 577 398 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R50

  Curing Through Cooperation: Aligning Cooperative Groups to Investigate Novel Therapeutic Approaches to Cure Plasma Cell Dyscrasias

  Utah State Higher Education System--University of Utah· Salt Lake City, Egyesült Államok· 173 767 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R44

  Detection and Isolation of Circulating Myeloma Cells: Toward a Minimally-Invasive CLIA-Certified Diagnostic for Multiple Myeloma

  Cellsbin, Inc.· Branford, Egyesült Államok· 1 045 925 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · U01

  Comparative Modeling of Multiple Myeloma Prevention, Early Detection and Treatment Interventions

  Washington University· Saint Louis, Egyesült Államok· 848 978 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Overcoming CAR T cell resistance by tumor-restricted IL-12 driven anti-tumor immunity

  University of California Los Angeles· Los Angeles, Egyesült Államok· 477 666 USD awarded in fiscal year 2026· until 2031. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting EP300/CBP in AML: from mechanistic discovery to therapeutic innovation (EPIC-AML)

  Universita Degli Studi di Parma· Parma, Olaszország· EU contribution 193 643 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding the immuno-regulatory functions of the human bone marrow niche upon cancer cellular therapy (ImmunhOss)

  Lunds Universitet· Lund, Svédország· EU contribution 2 000 000 EUR· until 2032. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Microbiome-Driven Modulation of Immune Reconstitution and Vaccine Responsiveness in Multiple Myeloma Patients following Stem Cell Transplantation (MicroMM)

  Technische Universitaet Muenchen· Muenchen, Németország· EU contribution 1 466 571 EUR· until 2031. okt.

• European Commission (Horizon Europe) · HORIZON-RIA

  iNK Cell–Driven Strategies for Enhanced Multiple Myeloma ImmunotherapY (iN-KEY)

  Banc de Sang I Teixits· Barcelona, Spanyolország· EU contribution 9 998 178 EUR· until 2031. szept.· 5 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  A CEllulaR immunoTherapy virtuAl twin for personalIsed cancer treatmeNT (CERTAINTY)

  Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung Ev· Munchen, Németország· EU contribution 9 999 253 EUR· until 2028. máj.· 8 countries

10 of 334 running projects, newest first. Listed amounts together: 235,6 M USD + 35,6 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

  NCT03530683· Pfizer· Frissítve: 2024. szept. 3.

  “A business decision was made by Pfizer to terminate the study. Termination was not due to any safety concerns, requests from regulatory authorities, changes to the benefit/risk profile or any new concerns regarding the investigational product.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 23
• Organoids 3
• Mendelian Randomization Analysis 10
• CRISPR-Cas Systems 8
• Gene Expression Profiling 44
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 4
• Exome Sequencing 3
• Proteomics 15
• Metabolomics 10
• Mass Spectrometry 7
• Flow Cytometry 48
• Immunohistochemistry 11
• Liquid Biopsy 2
• Circulating Tumor DNA 2
• Xenograft Model Antitumor Assays 78
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 26
• Machine Learning 17
• Deep Learning 6
• Cohort Studies 32
• Genome-Wide Association Study 7

• PFAS penetrate the bone marrow microenvironment and alter immunometabolic homeostasis.

  Environ Pollut, 2026. aug.

• Metabolic heterogeneity and niche rewiring in bone marrow plasma cells from patients with MGUS, solitary bone plasmacytoma and multiple myeloma.

  Blood Cancer J, 2026. jún.

• N-Acetylornithine Depletion in Bone Marrow Biopsy: A Novel Microenvironment-Specific Hallmark for Multiple Myeloma Diagnosis.

  Int J Lab Hematol, 2026. ápr.

• Integrating Bidirectional Mendelian Randomization with Multi-Omics Reveals Causal Serum Metabolites and Novel Metabolic Drivers of Multiple Myeloma.

  Int J Mol Sci, 2026. febr.

• Causal Effects of Hydrophilic Bile Acids on Carfilzomib-Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study.

  Clin Pharmacol Ther, 2026. febr.

• Multi-omics profiling and AI-driven clinically deployable risk models in MGUS and smoldering myeloma.

  Clin Exp Med, 2025. dec.

• [Metabolic Characteristics of Multiple Myeloma Based on Non-Targeted Metabolomics].

  Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2025. dec.

• Metabolomic Investigation of Myelodysplastic Syndromes, Multiple Myeloma, and Homozygous β-Thalassemia.

  Cells, 2025. nov.

• Beyond single biomarkers: multi-omics strategies to predict immunotherapy outcomes in blood cancers.

  Clin Exp Med, 2025. nov.

• [Progress in metabolomics of multiple myeloma].

  Zhonghua Xue Ye Xue Za Zhi, 2025. okt.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.